Reviewed against published clinical evidence | Always consult a qualified healthcare professional before starting, stopping, or changing any medication.
| Key Takeaways |
| • Both dulaglutide and liraglutide are GLP-1 receptor agonists proven to lower blood sugar and support weight loss in type 2 diabetes. |
| • Dulaglutide is injected once a week; liraglutide is injected once daily — a difference that can influence which fits your routine. |
| • Both carry cardiovascular benefits and similar side effect profiles; the right choice depends on your health goals, lifestyle, and your doctor’s guidance. |
If your doctor has mentioned either of these injections, or you’ve come across the names Trulicity and Victoza on your own then you’re in the right place.
This guide walks through every meaningful difference, side by side, so you and your doctor can have a more informed conversation.
1. What Exactly Are Dulaglutide and Liraglutide?
Both belong to a class of medicines called GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). These drugs mimic a hormone your gut naturally releases after eating.
GLP-1 hormone does three things at once: it tells your pancreas to release insulin when blood sugar rises, it slows the rate at which your stomach empties food into your intestine, and it signals your brain that you’re full.
GLP-1 receptor agonists replicate all three actions, which is why they help both blood sugar control and weight management.
Dulaglutide is sold under the brand name Trulicity (manufactured by Eli Lilly) and is injected once a week.
Liraglutide is sold as Victoza for type 2 diabetes and Saxenda for weight management (both by Novo Nordisk) and is injected once daily.
In India, both medications are available on prescription. Victoza (liraglutide) was also approved under the brand name Lirafit, launched by Glenmark Pharmaceuticals in January 2024.
Trulicity (dulaglutide) is accessible through licensed importers and specialist endocrinology centres. For a full overview of dulaglutide, see our complete dulaglutide guide. Both require a valid doctor’s prescription.
| Feature | Dulaglutide (Trulicity) | Liraglutide (Victoza / Saxenda) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brand names (India context) | Trulicity | Victoza (diabetes), Saxenda (weight), Lirafit |
| Manufacturer | Eli Lilly | Novo Nordisk / Glenmark (Lirafit) |
| Injection frequency | Once weekly | Once daily |
| Approved for type 2 diabetes | Yes | Yes |
| Approved for weight management | Higher doses (3 mg, 4.5 mg) — US/EU | Yes (Saxenda, 3 mg) |
| Administration device | Pre-filled auto-injector pen | Multi-dose injection pen |
Sources: Eli Lilly Trulicity Prescribing Information; PharmEasy – Liraglutide Guide
2. How Do They Work in Your Body?
The mechanism is the same for both. Each drug binds to GLP-1 receptors found on pancreatic beta cells, in the brain’s appetite centres, and in the gut wall.
When the receptor is activated, three parallel effects occur:
- Glucose-dependent insulin secretion: the pancreas releases more insulin — but only when blood sugar is already elevated, which keeps the risk of hypoglycaemia (dangerously low blood sugar) low.
- Glucagon suppression: less glucagon is released, so the liver produces less glucose — particularly important after meals.
- Delayed gastric emptying: food moves more slowly from the stomach into the small intestine, blunting post-meal blood sugar spikes and extending the sensation of fullness.
Centrally, both drugs also act on appetite-regulating regions of the brain, reducing hunger and caloric intake.
This dual peripheral-and-central action is why GLP-1 receptor agonists produce meaningful weight loss alongside blood sugar benefits.
The key structural difference between the two drugs is their half-life. Liraglutide’s half-life is approximately 13 hours, requiring daily dosing.
Dulaglutide is engineered with a modified structure that extends its half-life to roughly 4 to 5 days, allowing a single weekly injection to maintain therapeutic levels throughout the week.
3. Dosing Schedules: Once a Week vs Once a Day
This is the most practically significant difference between the two drugs, and it affects daily routine more than any other factor.
Dulaglutide dosing
Dulaglutide starts at 0.75 mg subcutaneously once weekly. After at least 4 weeks, the dose may be increased to 1.5 mg once weekly for additional glycaemic control.
Higher doses of 3 mg and 4.5 mg once weekly are approved in certain markets for further benefit.
The injection can be given on any day of the week, and the day can be changed as long as the next dose is at least 3 days away.
If a dose is missed, it should be taken as soon as possible, provided the next scheduled dose is at least 3 days away. If not, skip the missed dose and resume the regular schedule.
Liraglutide dosing
Liraglutide follows a structured escalation schedule to reduce gastrointestinal side effects:
- Week 1: 0.6 mg once daily (initiation dose is not therapeutically effective on its own, but allows the body to adjust)
- Week 2: 1.2 mg once daily
- Week 3 onward: 1.8 mg once daily (standard diabetes dose)
- For weight management (Saxenda): escalation continues to 3 mg once daily over 5 weeks
| Dosing Factor | Dulaglutide | Liraglutide |
|---|---|---|
| Frequency | Once weekly | Once daily |
| Starting dose | 0.75 mg/week | 0.6 mg/day |
| Standard therapeutic dose | 1.5 mg/week | 1.2–1.8 mg/day |
| Maximum dose (diabetes) | 4.5 mg/week (select markets) | 1.8 mg/day |
| Maximum dose (weight mgmt) | 4.5 mg/week (US/EU) | 3.0 mg/day (Saxenda) |
| Injection site | Abdomen, thigh, or upper arm | Abdomen, thigh, or upper arm |
| Missed dose rule | Take if ≥3 days remain before next dose | Take same day; do not double dose |
| Device type | Single-use auto-injector pen | Multi-dose pen with needle attachment |
Sources: Drugs.com – Dulaglutide Dosage; Drugs.com – Liraglutide Dosage; MedlinePlus – Dulaglutide
4. How Effective Are They? Blood Sugar and Weight Loss, Compared
This is the heart of the comparison — and the research data provides a nuanced, evidence-grounded answer.
Blood sugar control (HbA1c reduction)
The landmark head-to-head clinical trial between these two drugs is the AWARD-6 trial, published in The Lancet (2014).
This Phase 3, randomised, open-label trial enrolled 599 patients with type 2 diabetes inadequately controlled on metformin across 62 sites in nine countries.
At 26 weeks, dulaglutide 1.5 mg once weekly reduced HbA1c by a mean of 1.42%, compared with 1.36% for liraglutide 1.8 mg once daily.
The mean treatment difference was 0.06%, within the pre-specified non-inferiority margin of 0.4%. Dulaglutide was confirmed as non-inferior to liraglutide’s highest approved diabetes dose.
Real-world evidence supports this conclusion. A multi-institutional cohort study from Asia (published in Cardiovascular Diabetology, 2020) followed 3,025 patients and found that at 12 months, dulaglutide reduced HbA1c by 1.06% versus 0.83% with liraglutide which was a statistically significant difference, though both achieved meaningful control.
Weight loss
Here the picture is more nuanced. In the AWARD-6 trial, liraglutide produced greater weight loss than dulaglutide.
Liraglutide is also approved at a dedicated weight-management dose of 3 mg/day (as Saxenda), which goes beyond the diabetes dose.
Dulaglutide’s labelling in select markets now includes higher doses (3 mg, 4.5 mg) for additional metabolic benefit, though the primary indication remains blood sugar management.
The SCALE Obesity and Prediabetes trial (published in New England Journal of Medicine, 2015), with 3,731 participants, showed liraglutide 3.0 mg produced a mean weight reduction of 8.0% from baseline at 56 weeks, compared with 2.6% in the placebo group.
Approximately 63.2% of liraglutide-treated participants lost at least 5% of their body weight.
The real-world comparative data on weight loss between the two drugs is largely comparable. A systematic review and meta-analysis found similar effects on weight reduction between dulaglutide and liraglutide across 6- and 12-month follow-ups when used for diabetes management.
| Outcome | Dulaglutide | Liraglutide | Key Source |
|---|---|---|---|
| HbA1c reduction (diabetes dose) | −1.42% (AWARD-6, 26 wk) | −1.36% (AWARD-6, 26 wk) | AWARD-6, The Lancet 2014 |
| Weight loss (diabetes dose, 12 mo) | ~1.1 kg (Asian cohort) | ~1.6 kg (Asian cohort) | Cardiovascular Diabetology 2020 |
| Weight loss (dedicated weight dose) | Higher doses under study | −8.0% body weight (3 mg/day) | SCALE Trial, NEJM 2015 |
| % achieving HbA1c <7% (diabetes) | Comparable between groups | Comparable between groups | AWARD-6 |
| Systolic BP reduction | −2.47 mmHg (significant) | Not statistically significant | Asian cohort 2020 |
Bottom line on effectiveness: For blood sugar control in type 2 diabetes, both drugs perform comparably.
For weight management as a primary goal, liraglutide at 3 mg has the most established evidence base at this stage. For a broader comparison of GLP-1 agents including semaglutide, see our semaglutide vs dulaglutide guide.
5. Side Effects: What Should You Actually Expect?
The side effect profiles of dulaglutide and liraglutide overlap significantly — which makes sense, given that they work through the same receptor.
That said, there are clinically meaningful differences in severity and frequency.
Most common side effects (both drugs)
- Nausea — the most frequently reported effect, particularly in the first 2 to 4 weeks
- Diarrhoea
- Vomiting
- Decreased appetite
- Abdominal discomfort or bloating
- Fatigue, particularly during dose escalation
- Injection-site reactions (minor redness or discomfort)
For dulaglutide, a 2022 FDA adverse event analysis published in Frontiers found that nausea typically occurred within the first 2 to 3 days after the first injection and generally resolved after 2 weeks.
Fewer than 2% of patients needed to discontinue treatment due to nausea alone.
Liraglutide’s gastrointestinal side effects tend to be more pronounced. The same real-world database analysis found liraglutide had a severe gastrointestinal adverse event rate of 23.31%, compared to 12.29% for dulaglutide.
Liraglutide also showed the highest signal for upper abdominal pain and pancreatitis among GLP-1 receptor agonists studied.
Less common but serious side effects
- Pancreatitis: stop the medication immediately and seek medical attention if you develop severe, persistent abdominal pain, with or without nausea. This applies to both drugs.
- Gallbladder problems: both drugs may increase the risk of gallstones. Report any upper-right abdominal pain or jaundice to your doctor.
- Kidney function: dehydration from vomiting or diarrhoea can strain the kidneys. Stay well hydrated, especially during the first weeks of treatment.
- Increased heart rate: a small increase in resting heart rate has been observed with both drugs. Inform your doctor if you notice persistent palpitations.
- Thyroid C-cell tumours: animal studies have shown a dose-dependent increase in thyroid C-cell tumours with both dulaglutide and liraglutide. Both are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
| Side Effect | Dulaglutide | Liraglutide |
|---|---|---|
| Nausea (any grade) | 8–29% of patients | 15–40% of patients |
| Severe GI adverse events | 12.29% (FAERS database) | 23.31% (FAERS database) |
| Pancreatitis signal | Present; monitor carefully | Highest signal among GLP-1 RAs studied |
| Upper abdominal pain | Reported | Highest signal among GLP-1 RAs studied |
| Thyroid C-cell caution | Contraindicated in MEN2 / MTC history | Contraindicated in MEN2 / MTC history |
| Hypoglycaemia risk | Low (glucose-dependent mechanism) | Low (glucose-dependent mechanism) |
Sources: FDA Adverse Event Reporting System Analysis, PMC 2022; Trulicity Side Effects – Lilly; Mayo Clinic – Dulaglutide
Talk with your doctor before starting either medication if you have a history of pancreatitis, thyroid disease, gallbladder problems, or severe gastrointestinal conditions.
6. Do They Protect Your Heart? The Cardiovascular Evidence
Both drugs have demonstrated cardiovascular benefits beyond blood sugar control. That has made GLP-1 receptor agonists a preferred class in treatment guidelines for people with type 2 diabetes and heart disease risk.
Liraglutide: The LEADER trial
The LEADER cardiovascular outcomes trial enrolled 9,340 adults with type 2 diabetes and high cardiovascular risk.
Over a median follow-up of 3.8 years, liraglutide significantly reduced the composite of major adverse cardiovascular events (MACE) like heart attack, stroke, or cardiovascular death with a hazard ratio of 0.87 (95% CI 0.78 to 0.97, p = 0.01 for superiority). The benefit was primarily driven by a reduction in cardiovascular mortality.
Dulaglutide: The REWIND trial
The REWIND trial (published in The Lancet, 2019) enrolled 9,901 adults with type 2 diabetes at 371 sites across 24 countries.
This trial included a broader population; the majority had cardiovascular risk factors but not necessarily established cardiovascular disease. Over a median follow-up of 5.4 years, dulaglutide reduced MACE with a comparable effect, largely driven by a lower incidence of non-fatal stroke.
A comparative analysis published in Scientific Reports (2024) concluded that cardiovascular outcomes between liraglutide and dulaglutide were broadly comparable in Asian patients with type 2 diabetes when studied in real-world settings, with both achieving meaningful MACE reduction.
One important distinction: LEADER enrolled a higher-risk cardiovascular population (81% with established cardiovascular disease), while REWIND’s population included more patients with only risk factors.
This affects how the numbers compare directly across trials.
| Trial | Drug | Population | Follow-up | MACE Reduction |
|---|---|---|---|---|
| LEADER | Liraglutide | 9,340 adults; 81% with established CVD | 3.8 years | HR 0.87 (13% relative reduction) |
| REWIND | Dulaglutide | 9,901 adults; mix of CVD + risk factors | 5.4 years | HR 0.88 (~12% relative reduction) |
Sources: REWIND Trial – The Lancet 2019; Comparative CV Outcomes – Scientific Reports 2024
7. Which One Might Be Right for You? A Practical Framework
No medication is universally “better.” The right choice depends on your daily schedule, your primary health goal, your tolerance for side effects, and what’s accessible where you live.
Here is a practical framework to take into a conversation with your doctor.
Consider dulaglutide if…
- Your schedule makes a daily injection difficult to maintain consistently
- You have had significant nausea with other GLP-1 medications — dulaglutide’s severe GI event rate is meaningfully lower
- You prefer a single-step auto-injector pen with no needle attachment required
- Your primary goal is blood sugar control, with weight management as a secondary benefit
Consider liraglutide if…
- Weight management is a co-equal or primary goal alongside diabetes control (Saxenda at 3 mg has a dedicated, robust evidence base)
- Your doctor recommends it based on your cardiovascular risk profile — LEADER enrolled a notably high-risk cardiac population with strong outcomes
- You are comfortable with a daily injection and prefer the dose-flexibility of a multi-dose pen
- You are in a setting where liraglutide has been available longer and your endocrinologist has greater familiarity with titration protocols
A note on lifestyle fit: A once-weekly injection fits more naturally into a busy lifestyle than a daily one. Missing a single liraglutide dose disrupts 24 hours of coverage; missing a single dulaglutide dose. If caught in time it has a 3-day correction window.
For those managing demanding work schedules or frequent travel, this distinction is practically meaningful.
Always discuss your full medical history including thyroid history, kidney function, gallbladder health, and current medications, with your doctor before starting either drug.
These medications interact with several other agents, and dose adjustments to existing diabetes medications may be needed.
The Bottom Line
Dulaglutide and liraglutide are closely matched in their ability to lower blood sugar and reduce cardiovascular risk; the landmark AWARD-6 trial confirmed they perform within a statistically equivalent range for HbA1c reduction.
The clearest practical difference is dosing frequency: once a week versus once a day.
Liraglutide carries a stronger weight-loss indication at its dedicated 3 mg dose, while dulaglutide may be better tolerated from a gastrointestinal standpoint for many patients.
Neither drug should be started without a prescription and ongoing medical supervision.
If you’re exploring options for type 2 diabetes management or weight-related goals, the next step is a conversation with an endocrinologist or your primary care physician, ideally one with access to your recent HbA1c levels, weight history, and cardiovascular risk profile.
Frequently Asked Questions
Is dulaglutide or liraglutide better for weight loss?
Liraglutide has a dedicated weight-management formulation (Saxenda, 3 mg/day) with strong clinical evidence, including the SCALE Obesity and Prediabetes trial showing a mean weight reduction of 8.0% at 56 weeks.
Dulaglutide is approved at higher doses (3 mg, 4.5 mg) in select markets and shows comparable weight effects at diabetes doses.
For weight management as a primary goal, discuss liraglutide’s dedicated formulation with your doctor. If semaglutide-based options like Ozempic or Wegovy, or tirzepatide (Mounjaro) for even greater weight loss potential, may be a better fit, the MetaGo weight loss program can help you explore clinician-supervised options.
What is the main difference between dulaglutide and liraglutide?
The most important practical difference is injection frequency: dulaglutide is injected once a week, while liraglutide requires a daily injection.
Both belong to the same drug class, work through the same mechanism, and produce broadly comparable reductions in blood sugar and cardiovascular risk.
Are dulaglutide and liraglutide available in India?
Yes, both are available in India on prescription. Liraglutide is accessible as Victoza (for diabetes) and was approved under the brand name Lirafit (Glenmark Pharmaceuticals) in January 2024.
Dulaglutide (Trulicity) is available through licensed import specialists and some endocrinology centres. Confirm current local availability and access requirements with your doctor or a licensed pharmacist.
How do the side effects of dulaglutide and liraglutide compare?
Both drugs share a similar gastrointestinal side effect profile: nausea, diarrhoea, and vomiting, especially during the first few weeks.
However, data from the FDA’s adverse event database suggests liraglutide has a higher rate of severe gastrointestinal events (23.31%) compared to dulaglutide (12.29%). Both are contraindicated in individuals with a history of medullary thyroid carcinoma or MEN2. Always report persistent or severe symptoms to your doctor promptly.
Can dulaglutide or liraglutide be used if I also have heart disease?
Both drugs have demonstrated cardiovascular benefits in large randomised trials (LEADER for liraglutide, REWIND for dulaglutide).
Both are associated with a reduction in major adverse cardiovascular events. Your doctor will weigh your specific cardiovascular risk profile, other medications, and medical history to determine which if either is appropriate for you. For a detailed side-by-side of semaglutide and Trulicity, see our Ozempic vs Trulicity guide.
